272 related articles for article (PubMed ID: 32394425)
1. Hypertrophic lichenoid dermatitis immune-related adverse event during combined immune checkpoint and exportin inhibitor therapy: A diagnostic pitfall for superficially invasive squamous cell carcinoma.
Marques-Piubelli ML; Tetzlaff MT; Nagarajan P; Duke TC; Glitza Oliva IC; Ledesma DA; Aung PP; Torres-Cabala CA; Wistuba II; Prieto VG; Nelson KC; Curry JL
J Cutan Pathol; 2020 Oct; 47(10):954-959. PubMed ID: 32394425
[TBL] [Abstract][Full Text] [Related]
2. Lichenoid dermatitis from immune checkpoint inhibitor therapy: An immune-related adverse event with mycosis-fungoides-like morphologic and molecular features.
Tetzlaff MT; Tang S; Duke T; Grabell DA; Cabanillas ME; Zuo Z; Yao JC; Nagarajan P; Aung PP; Torres-Cabala CA; Duvic M; Prieto VG; Huen A; Curry JL
J Cutan Pathol; 2019 Nov; 46(11):872-877. PubMed ID: 31254410
[TBL] [Abstract][Full Text] [Related]
3. Narrowband ultraviolet B therapy for refractory immune-related lichenoid dermatitis on PD-1 therapy: a case report.
Esfahani K; Henderson Berg MH; Zargham H; Billick R; Pehr K; Redpath M; Roshdy O; Miller WH
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33771890
[TBL] [Abstract][Full Text] [Related]
4. Lichenoid Dermatologic Toxicity From Immune Checkpoint Blockade Therapy: A Detailed Examination of the Clinicopathologic Features.
Tetzlaff MT; Nagarajan P; Chon S; Huen A; Diab A; Omar P; Aung PP; Torres-Cabala CA; Mays SR; Prieto VG; Curry JL
Am J Dermatopathol; 2017 Feb; 39(2):121-129. PubMed ID: 28134729
[TBL] [Abstract][Full Text] [Related]
5. Digital ulcerative lichenoid dermatitis in a patient receiving anti-PD-1 therapy.
Martínez-Doménech Á; García-Legaz Martínez M; Magdaleno-Tapial J; Valenzuela-Oñate C; Pérez-Pastor G; Pérez-Ferriols A
Dermatol Online J; 2019 Sep; 25(9):. PubMed ID: 31738845
[TBL] [Abstract][Full Text] [Related]
6. Gene expression profiling of lichenoid dermatitis immune-related adverse event from immune checkpoint inhibitors reveals increased CD14
Curry JL; Reuben A; Szczepaniak-Sloane R; Ning J; Milton DR; Lee CH; Hudgens C; George S; Torres-Cabala C; Johnson D; Subramanya S; Wargo JA; Mudaliar K; Wistuba II; Prieto VG; Diab A; Tetzlaff MT
J Cutan Pathol; 2019 Sep; 46(9):627-636. PubMed ID: 30883858
[TBL] [Abstract][Full Text] [Related]
7. Histologic Assessment of Lichenoid Dermatitis Observed in Patients With Advanced Malignancies on Antiprogramed Cell Death-1 (anti-PD-1) Therapy With or Without Ipilimumab.
Chou S; Hwang SJ; Carlos G; Wakade D; Fernandez-Penas P
Am J Dermatopathol; 2017 Jan; 39(1):23-27. PubMed ID: 28045749
[TBL] [Abstract][Full Text] [Related]
8. Clinical and Histologic Features of Lichenoid Mucocutaneous Eruptions Due to Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Immunotherapy.
Shi VJ; Rodic N; Gettinger S; Leventhal JS; Neckman JP; Girardi M; Bosenberg M; Choi JN
JAMA Dermatol; 2016 Oct; 152(10):1128-1136. PubMed ID: 27411054
[TBL] [Abstract][Full Text] [Related]
9. Oral lichenoid reaction showing multiple ulcers associated with anti-programmed death cell receptor-1 treatment: A report of two cases and published work review.
Obara K; Masuzawa M; Amoh Y
J Dermatol; 2018 May; 45(5):587-591. PubMed ID: 29352490
[TBL] [Abstract][Full Text] [Related]
10. Pembrolizumab-induced pseudoepitheliomatous eruption consistent with hypertrophic lichen planus.
Coscarart A; Martel J; Lee MP; Wang AR
J Cutan Pathol; 2020 Mar; 47(3):275-279. PubMed ID: 31589773
[TBL] [Abstract][Full Text] [Related]
11. Characterization of dermatitis after PD-1/PD-L1 inhibitor therapy and association with multiple oncologic outcomes: A retrospective case-control study.
Min Lee CK; Li S; Tran DC; Zhu GA; Kim J; Kwong BY; Chang ALS
J Am Acad Dermatol; 2018 Dec; 79(6):1047-1052. PubMed ID: 29857011
[TBL] [Abstract][Full Text] [Related]
12. Immune checkpoint inhibitor lichenoid eruption due to pembrolizumab.
McCormick BJ; Zieman D; West-Santos C; Phillips MB
BMJ Case Rep; 2023 Jun; 16(6):. PubMed ID: 37339826
[TBL] [Abstract][Full Text] [Related]
13. Timing of Onset of Adverse Cutaneous Reactions Associated With Programmed Cell Death Protein 1 Inhibitor Therapy.
Wang LL; Patel G; Chiesa-Fuxench ZC; McGettigan S; Schuchter L; Mitchell TC; Ming ME; Chu EY
JAMA Dermatol; 2018 Sep; 154(9):1057-1061. PubMed ID: 30027278
[TBL] [Abstract][Full Text] [Related]
14. Dermatologic toxicities to immune checkpoint inhibitor therapy: A review of histopathologic features.
Ellis SR; Vierra AT; Millsop JW; Lacouture ME; Kiuru M
J Am Acad Dermatol; 2020 Oct; 83(4):1130-1143. PubMed ID: 32360716
[TBL] [Abstract][Full Text] [Related]
15. Cutaneous Immune-Related Adverse Events (irAEs) to Immune Checkpoint Inhibitors: A Dermatology Perspective on Management [Formula: see text].
Muntyanu A; Netchiporouk E; Gerstein W; Gniadecki R; Litvinov IV
J Cutan Med Surg; 2021; 25(1):59-76. PubMed ID: 32746624
[TBL] [Abstract][Full Text] [Related]
16. Rare and fatal complication of immune checkpoint inhibition: a case report of haemophagocytic lymphohistiocytosis with severe lichenoid dermatitis.
Choi S; Zhou M; Bahrani E; Martin BA; Ganjoo KN; Zaba LC
Br J Haematol; 2021 Jun; 193(6):e44-e47. PubMed ID: 33954981
[No Abstract] [Full Text] [Related]
17. PD1 inhibitor induced inverse lichenoid eruption: a case series.
Sethi M; Garg V; Lee JB; Yang S
Dermatol Online J; 2020 Dec; 26(12):. PubMed ID: 33423421
[TBL] [Abstract][Full Text] [Related]
18. Generalized morphoea in the setting of combined immune checkpoint inhibitor therapy for metastatic melanoma: A case report.
Langan EA; Budner K; Zillikens D; Terheyden P
Medicine (Baltimore); 2021 Apr; 100(16):e25513. PubMed ID: 33879687
[TBL] [Abstract][Full Text] [Related]
19. Lichenoid dermatitis in three patients with metastatic melanoma treated with anti-PD-1 therapy.
Joseph RW; Cappel M; Goedjen B; Gordon M; Kirsch B; Gilstrap C; Bagaria S; Jambusaria-Pahlajani A
Cancer Immunol Res; 2015 Jan; 3(1):18-22. PubMed ID: 25287118
[TBL] [Abstract][Full Text] [Related]
20. Immune-Checkpoint Induced Skin Toxicity Masked as Squamous Cell Carcinoma: Case Report on Mimickers of Dermatological Toxicity with PD-1 Inhibition.
Chan SWS; Shukla R; Ramsay J; McWhirter E; Barnfield P; Juergens RA
Curr Oncol; 2023 Apr; 30(5):4527-4537. PubMed ID: 37232800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
